151 related articles for article (PubMed ID: 35117921)
1. Protein tyrosine phosphatase receptor type delta (PTPRD) suppresses the expression of PD-L1 in human hepatocellular carcinoma by down-regulating STAT3.
Meng Q; Tian J; Qin F; Huang X; Zhu D; Xiang B; Dong M
Transl Cancer Res; 2020 Sep; 9(9):5574-5584. PubMed ID: 35117921
[TBL] [Abstract][Full Text] [Related]
2. Protein tyrosine phosphatase receptor type D (PTPRD)-mediated signaling pathways for the potential treatment of hepatocellular carcinoma: a narrative review.
Huang X; Qin F; Meng Q; Dong M
Ann Transl Med; 2020 Sep; 8(18):1192. PubMed ID: 33241041
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of M2 type macrophage-derived extracellular vesicles regulating PD-L1 expression via the MISP/IQGAP1 axis in hepatocellular carcinoma immunotherapy resistance.
Wang X; Ye X; Chen Y; Lin J
Int Immunopharmacol; 2023 Nov; 124(Pt A):110848. PubMed ID: 37633233
[TBL] [Abstract][Full Text] [Related]
4. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
5. Modified Biejia Jianwan decoction restrains PD-L1-mediated immune evasion through the HIF-1α/STAT3/NF-κB signaling pathway.
Tian X; Liu F; Wang Z; Zhang J; Liu Q; Zhang Y; Zhang D; Huang C; Zhao J; Jiang S
J Ethnopharmacol; 2024 Mar; 322():117577. PubMed ID: 38104877
[TBL] [Abstract][Full Text] [Related]
6. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.
Zhang W; Liu Y; Yan Z; Yang H; Sun W; Yao Y; Chen Y; Jiang R
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581055
[TBL] [Abstract][Full Text] [Related]
7. Chrysin inhibits hepatocellular carcinoma progression through suppressing programmed death ligand 1 expression.
Rong W; Wan N; Zheng X; Shi G; Jiang C; Pan K; Gao M; Yin Z; Gao ZJ; Zhang J
Phytomedicine; 2022 Jan; 95():153867. PubMed ID: 34923234
[TBL] [Abstract][Full Text] [Related]
8. lncRNA MIAT targets miR-411-5p/STAT3/PD-L1 axis mediating hepatocellular carcinoma immune response.
Zhang X; Pan B; Qiu J; Ke X; Shen S; Wang X; Tang N
Int J Exp Pathol; 2022 Jun; 103(3):102-111. PubMed ID: 35429078
[TBL] [Abstract][Full Text] [Related]
9. miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis.
Van Renne N; Roca Suarez AA; Duong FHT; Gondeau C; Calabrese D; Fontaine N; Ababsa A; Bandiera S; Croonenborghs T; Pochet N; De Blasi V; Pessaux P; Piardi T; Sommacale D; Ono A; Chayama K; Fujita M; Nakagawa H; Hoshida Y; Zeisel MB; Heim MH; Baumert TF; Lupberger J
Gut; 2018 May; 67(5):953-962. PubMed ID: 28159835
[TBL] [Abstract][Full Text] [Related]
10. Paeoniflorin inhibits hepatocellular carcinoma growth by reducing PD-L1 expression.
Gao M; Zhang D; Jiang C; Jin Q; Zhang J
Biomed Pharmacother; 2023 Oct; 166():115317. PubMed ID: 37597322
[TBL] [Abstract][Full Text] [Related]
11. The EGFR-P38 MAPK axis up-regulates PD-L1 through miR-675-5p and down-regulates HLA-ABC via hexokinase-2 in hepatocellular carcinoma cells.
Liu Z; Ning F; Cai Y; Sheng H; Zheng R; Yin X; Lu Z; Su L; Chen X; Zeng C; Wang H; Liu L
Cancer Commun (Lond); 2021 Jan; 41(1):62-78. PubMed ID: 34236149
[TBL] [Abstract][Full Text] [Related]
12. Loss of Tyrosine Phosphatase Delta Promotes Gastric Cancer Progression via Signal Transducer and Activator of Transcription 3 Pathways.
Wu L; Gao L; Kong D; Xue H
Dig Dis Sci; 2019 Nov; 64(11):3164-3172. PubMed ID: 31041642
[TBL] [Abstract][Full Text] [Related]
13. Humanized disulfide-stabilized diabody against fibroblast growth factor-2 inhibits PD-L1 expression and epithelial-mesenchymal transition in hepatoma cells through STAT3.
Sun H; Song X; Li C; Li Q; Liu S; Deng N
IUBMB Life; 2023 Nov; 75(11):957-968. PubMed ID: 37489553
[TBL] [Abstract][Full Text] [Related]
14. microRNA-378a-3p regulates the progression of hepatocellular carcinoma by regulating PD-L1 and STAT3.
Li Y; Zhou T; Cheng X; Li D; Zhao M; Zheng WV
Bioengineered; 2022 Mar; 13(3):4730-4743. PubMed ID: 35184646
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of PD-L1 expression promotes epithelial-to-mesenchymal transition in sorafenib-resistant hepatocellular carcinoma cells.
Xu GL; Ni CF; Liang HS; Xu YH; Wang WS; Shen J; Li MM; Zhu XL
Gastroenterol Rep (Oxf); 2020 Oct; 8(5):390-398. PubMed ID: 33163195
[TBL] [Abstract][Full Text] [Related]
16. Expression of tumor-associated macrophages and PD-L1 in patients with hepatocellular carcinoma and construction of a prognostic model.
Kong P; Yang H; Tong Q; Dong X; Yi MA; Yan D
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10685-10700. PubMed ID: 37306737
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib suppresses radioresistance and synergizes radiotherapy-mediated CD8
Cheng CC; Ho AS; Peng CL; Chang J; Sie ZL; Wang CL; Chen YL; Chen CY
Int Immunopharmacol; 2022 Nov; 112():109110. PubMed ID: 36037651
[TBL] [Abstract][Full Text] [Related]
18. [The expression and function of PD-L1 in CD133(+) human liver cancer stem-like cells].
Bai YD; Shi ML; Li SQ; Wang XL; Peng JJ; Zhou DJ; Sun FF; Li H; Wang C; Du M; Zhang T; Li D
Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):117-128. PubMed ID: 36781232
[No Abstract] [Full Text] [Related]
19. Lipopolysaccharide facilitates immune escape of hepatocellular carcinoma cells via m6A modification of lncRNA MIR155HG to upregulate PD-L1 expression.
Peng L; Pan B; Zhang X; Wang Z; Qiu J; Wang X; Tang N
Cell Biol Toxicol; 2022 Dec; 38(6):1159-1173. PubMed ID: 35438468
[TBL] [Abstract][Full Text] [Related]
20. HSF1 is involved in immunotherapeutic response through regulating APOJ/STAT3-mediated PD-L1 expression in hepatocellular carcinoma.
Cheng H; Wang S; Huang A; Ma J; Gao D; Li M; Chen H; Guo K
Cancer Biol Ther; 2023 Dec; 24(1):1-9. PubMed ID: 36482717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
